# Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events

Study · id `cardio:ct-nct01923818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01923818](<https://clinicaltrials.gov/study/NCT01923818>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01923818

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3700 participants.

## Technical summary

Registry record NCT01923818. Randomized; triple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 3700 participants (planned count; ClinicalTrials.gov record NCT01923818, source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01923818, source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)
- Primary completion: 2015-09 (anticipated) (ClinicalTrials.gov record NCT01923818, source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)
- Completion: 2016-04 (anticipated) (ClinicalTrials.gov record NCT01923818, source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01923818, source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01923818-2013-08-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- Acronym: TRACE
- Condition: Ischemic Stroke
- Condition: TIA
- Intervention (Drug): rivaroxaban
- Intervention (Drug): Aspirin
- Intervention (Drug): placebo
- Lead sponsor: Xijing Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Xijing Hospital (`cardio:org-xijing-hospital`)

## Provenance

Content hash: 9cf09b0e853166d0561beee7c21a6e2431c6725a184b57425a3061af909f172b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
